However, the drug had minimal or no effects in PC9, HCC827 (harboring EGFR active mutant), H460, A549 (KRAS mutation-positive), JFCR-256-3 (BRAF mutation-positive patient-derived cancer cells), and TIG-3 cells (normal human lung fibroblasts) (Fig. 2d and Supplementary Figs. 6, 7). The gene discussed is BRAF; the disease is cancer.